How did the Feb 27, 2025 $40M offering impact CRDF's short interest percentage?

Cardiff Oncology, Inc. (CRDF) completed a $40 million registered direct offering on February 27, 2025, which was oversubscribed and included participation from new and existing healthcare-dedicated investors.1

To assess the impact of this offering on CRDF's short interest percentage, it would be necessary to examine the short interest data reported for periods immediately before and after the February 27, 2025, offering date. Short interest data is typically published twice monthly by FINRA, with reporting periods usually ending around the 15th and the last day of each month.

While Fintel provides comprehensive short interest data for CRDF, including the current "Short Interest % Float" which stands at 31.75%,2 the specific historical short interest percentages for the reporting periods covering mid-February 2025 and mid-March 2025 are not available in the provided search snippets. Therefore, a direct quantification of the impact on short interest percentage immediately following the February 27, 2025 offering cannot be provided from the current information.

Investors interested in this specific data point would typically look for the short interest reports with settlement dates around February 14, 2025 (pre-offering) and February 28, 2025, or March 14, 2025 (post-offering) on the Fintel platform for CRDF.